FOXP3 and neoplasm: PARP inhibition promotes differentiation of naïve T cells to Foxp3+ regulatory T cells [104], which suppress immune responses, and upregulates in tumor cells the expression of PD-L1 [139,140], which by engaging PD1 dampens anti-tumor T cell responses favoring tumor immune-evasion.